Clinical Trials
48 trialsA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
ARC-25
Arcus Biosciences, Inc.
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
eVOLVE-02
AstraZeneca
EGRET
AstraZeneca
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
ELEVATE HNSCC
Gilead Sciences
ECLIPSE
Rakuten Medical, Inc.
KEYVIBE-005
Merck Sharp & Dohme LLC
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
MK-3475-048
Merck Sharp & Dohme LLC
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
INDUCE-4
GlaxoSmithKline
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
CheckMate 651
Bristol-Myers Squibb
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Shanghai Henlius Biotech
CHANGE2
Merck KGaA, Darmstadt, Germany
RESGEX
Glycotope GmbH
KESTREL
AstraZeneca
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Orient Europharma Co., Ltd.
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck(R/M SCCHN)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Celgene
A Study in Advanced Solid Tumors
Eli Lilly and Company
Study in Advanced Solid Tumors
Eli Lilly and Company
A Study in Head and Neck Cancer
Eli Lilly and Company
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NanoCarrier Co., Ltd.
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Amgen
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
Sanofi
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Genentech, Inc.
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Sanofi
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
CHANGE
Merck KGaA, Darmstadt, Germany
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
Merck KGaA, Darmstadt, Germany
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Merck KGaA, Darmstadt, Germany
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
Docetaxel in Head and Neck Cancer
Sanofi
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
Galectin Therapeutics Inc.
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
Sanofi
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sanofi